Gameto Announces FDA IND Clearance for Fertilo, the First iPSC-Based Therapy to Enter U.S. Phase 3 Clinical Trials ...

Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and ...

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...

Enveric Biosciences ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, ...

Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic health condition, such as arthritis. The rising prevalence of chronic pain drives market growth by ...

The team at UCLA is further developing this gene therapy approach in which a patient's own blood stem cells can be modified to add a healthy copy of ...

Wockhardt now intends to file a new drug application (NDA) with the USFDA and seek marketing authorisation application with ...

In the Opportunity Research report, analyst Rob Goldman reviews clinical and preclinical data on OKYO's lead candidate, the Company's inherent first-mover opportunities in the industry, upcoming ...

We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ...

According to a recently published survey, 13% of US adults said they felt very tired or exhausted, and this national fatigue might be linked to not getting enough of three essential nutrients: Vitamin ...

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company with a market capitalization of $156.6 million, is at a pivotal juncture in its development of programmed cellular ...